Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Other Non-Current Assets (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Other Non-Current Assets for 2 consecutive years, with $253000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 25.37% to $253000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $253000.0 through Dec 2025, down 25.37% year-over-year, with the annual reading at $253000.0 for FY2025, 25.37% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $253000.0 at NRX Pharmaceuticals, up from $243000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $441000.0 in Q1 2024, with the low at $243000.0 in Q3 2025.